SEC Info - Acadia Pharmaceuticals Inc - ‘10-Q’ for 6/30/15

SEC Info℠

Home

My Interests

Help

Please Sign In

Acadia Pharmaceuticals Inc – ‘10-Q’ for 6/30/15 – ‘EX-101.INS’

On: Thursday, 8/6/15, at 4:11pm ET · For: 6/30/15 · Accession #: 1193125-15-281018 · File #: 0-50768

Previous ‘10-Q’: ‘10-Q’ on 5/7/15 for 3/31/15 · Next: ‘10-Q’ on 11/5/15 for 9/30/15 · Latest: ‘10-Q’ on 5/9/24 for 3/31/24 · 21 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/06/15  Acadia Pharmaceuticals Inc        10-Q        6/30/15   43:1.7M                                   Donnelley … Solutions/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    346K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML     25K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     18K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     16K 
26: R1          Document and Entity Information                     HTML     36K 
18: R2          Condensed Consolidated Balance Sheets               HTML     82K 
24: R3          Condensed Consolidated Balance Sheets               HTML     37K 
                (Parenthetical)                                                  
28: R4          Condensed Consolidated Statements of Operations     HTML     41K 
39: R5          Condensed Consolidated Statements of Operations     HTML     21K 
                (Parenthetical)                                                  
19: R6          Condensed Consolidated Statements of Comprehensive  HTML     32K 
                Loss                                                             
23: R7          Condensed Consolidated Statements of Cash Flows     HTML     88K 
17: R8          Basis of Presentation                               HTML     24K 
13: R9          Net Loss Per Share                                  HTML     25K 
40: R10         Stock-Based Compensation                            HTML     21K 
30: R11         Accrued Liabilities                                 HTML     21K 
29: R12         Investment Securities                               HTML     34K 
34: R13         Fair Value Measurements                             HTML     39K 
35: R14         Stockholders' Equity                                HTML     25K 
33: R15         Commitments and Contingencies                       HTML     25K 
36: R16         Recent Accounting Pronouncements                    HTML     20K 
25: R17         Stock-Based Compensation (Policies)                 HTML     19K 
27: R18         Net Loss Per Share (Tables)                         HTML     23K 
32: R19         Accrued Liabilities (Tables)                        HTML     21K 
43: R20         Investment Securities (Tables)                      HTML     29K 
37: R21         Fair Value Measurements (Tables)                    HTML     33K 
21: R22         Basis of Presentation - Additional Information      HTML     18K 
                (Detail)                                                         
31: R23         Potential Common Shares Excluded in Calculating     HTML     25K 
                Basic and Diluted Net Loss Per Common Share                      
                (Detail)                                                         
22: R24         Stock-Based Compensation - Additional Information   HTML     29K 
                (Detail)                                                         
12: R25         Accrued Liabilities (Detail)                        HTML     30K 
38: R26         Investment Securities, All Classified as            HTML     40K 
                Available-for-Sale (Detail)                                      
41: R27         Fair Value Measurements - Additional Information    HTML     19K 
                (Detail)                                                         
15: R28         Fair Value Measurements of Cash Equivalents and     HTML     49K 
                Available-For-Sale Investment Securities (Detail)                
14: R29         Stockholders' Equity - Additional Information       HTML     32K 
                (Detail)                                                         
16: R30         Commitments and Contingencies - Additional          HTML     27K 
                Information (Detail)                                             
42: XML         IDEA XML File -- Filing Summary                      XML     70K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX     34K 
 5: EX-101.INS  XBRL Instance -- acad-20150630                       XML    389K 
 7: EX-101.CAL  XBRL Calculations -- acad-20150630_cal               XML    106K 
 8: EX-101.DEF  XBRL Definitions -- acad-20150630_def                XML    137K 
 9: EX-101.LAB  XBRL Labels -- acad-20150630_lab                     XML    432K 
10: EX-101.PRE  XBRL Presentations -- acad-20150630_pre              XML    283K 
 6: EX-101.SCH  XBRL Schema -- acad-20150630                         XSD     65K 
20: ZIP         XBRL Zipped Folder -- 0001193125-15-281018-xbrl      Zip     51K

‘EX-101.INS’ — XBRL Instance — acad-20150630

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="yes" encoding="windows-1252"?>

<xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="acad-20150630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase"/>

<dei:EntityCommonStockSharesOutstanding contextRef="eol_PE81806---1510-Q0007_STD_0_20150731_0" unitRef="shares" decimals="INF" id="id_5138751_88887BCF-A46D-4262-A6B7-B8A6F17F0ADF_2_5"> 100714851 </dei:EntityCommonStockSharesOutstanding>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE81806---1510-Q0007_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1002_27"> 13698000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_23"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:CommonStockSharesAuthorized contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_24"> 225000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:CommonStockSharesOutstanding contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_26"> 100522374 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_19"> 5000000 </us-gaap:PreferredStockSharesAuthorized>

<us-gaap:PreferredStockSharesIssued contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_20"> 0 </us-gaap:PreferredStockSharesIssued>

<us-gaap:CommonStockSharesIssued contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_25"> 100522374 </us-gaap:CommonStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_21"> 0 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_18"> 0.0001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:LiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_12"> 19378000 </us-gaap:LiabilitiesCurrent>

<us-gaap:AdditionalPaidInCapital contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_27"> 833696000 </us-gaap:AdditionalPaidInCapital>

<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_1_1"> 3528000 </us-gaap:EmployeeRelatedLiabilitiesCurrent>

<us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_11"> 16462000 </us-gaap:AccruedLiabilitiesCurrent>

<us-gaap:Liabilities contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_14"> 19718000 </us-gaap:Liabilities>

<us-gaap:LiabilitiesNoncurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_13"> 340000 </us-gaap:LiabilitiesNoncurrent>

<us-gaap:CommonStockValue contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_22"> 10000 </us-gaap:CommonStockValue>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_3_2"> 13000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_29"> 11000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:CommitmentsAndContingencies contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_15"/>

<us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_1_2"> 3666000 </us-gaap:AccruedProfessionalFeesCurrent>

<us-gaap:PreferredStockValue contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_17"/>

<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_1_3"> 1683000 </us-gaap:OtherAccruedLiabilitiesCurrent>

<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_28"> -577896000 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:StockholdersEquity contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_30"> 255821000 </us-gaap:StockholdersEquity>

<us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_31"> 275539000 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:AccountsPayableCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_10"> 2916000 </us-gaap:AccountsPayableCurrent>

<us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_6"> 1813000 </us-gaap:PropertyPlantAndEquipmentNet>

<us-gaap:AssetsCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_5"> 273393000 </us-gaap:AssetsCurrent>

<us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_BB0FAF56-9A1D-4919-B9D0-F03C613A76A6_1_0"> 270542000 </us-gaap:InvestmentsFairValueDisclosure>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-5" id="id_5138751_05632B07-EA3F-463E-9603-6F3DB4CB35B4_2001_1"> 86200000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1001_27"> 93212000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:Assets contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_8"> 275539000 </us-gaap:Assets>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_3_3"> 11000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_4"> 1108000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_3_1"> 177563000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:OtherAssetsNoncurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_7"> 333000 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:InterestReceivableCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_3"> 1508000 </us-gaap:InterestReceivableCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_1_2"> 177565000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<acad:AccruedClinicalDevelopmentServices contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_1_0"> 7585000 </acad:AccruedClinicalDevelopmentServices>

<us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1109902x1105250" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_7002_4"> 92977000 </us-gaap:InvestmentsFairValueDisclosure>

<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1109902x1105250_1113971x1108237" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_11002_1"> 92977000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>

<us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1109902x1110677" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_7003_4"> 177565000 </us-gaap:InvestmentsFairValueDisclosure>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1109902x1110677_1113760x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_9003_2"> 164894000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1109902x1110677_1113760x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_10003_3"> 12671000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<acad:PotentialFutureRegulatoryMilestonePayment contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1111699x1130942" unitRef="iso4217_USD" decimals="-5" id="id_5138751_56FF22F2-3752-4220-B192-1701C2CCDB39_1001_0"> 2500000 </acad:PotentialFutureRegulatoryMilestonePayment>

<acad:PotentialFutureRegulatoryMilestonePayment contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1111699x1151561" unitRef="iso4217_USD" decimals="INF" id="id_5138751_56FF22F2-3752-4220-B192-1701C2CCDB39_2001_1"> 8000000 </acad:PotentialFutureRegulatoryMilestonePayment>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1113760x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_9001_2"> 164894000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1113760x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_10001_3"> 12671000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1113971x1108237" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_11001_1"> 92977000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>

<us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1115253x1116460" unitRef="iso4217_USD" decimals="-5" id="id_5138751_5E1ECD22-45BC-4579-A63C-5323EE00C769_1001_0"> 29700000 </us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_1_2"> 13000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_1_3"> 10000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_1_1"> 164891000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_1_4"> 164894000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_2_3"> 1000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_2_1"> 12672000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20150630_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_2_4"> 12671000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE81806---1510-Q0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2001_26"> 11707000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_23"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:CommonStockSharesAuthorized contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_24"> 150000000 </us-gaap:CommonStockSharesAuthorized>

<us-gaap:CommonStockSharesOutstanding contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_26"> 100047331 </us-gaap:CommonStockSharesOutstanding>

<us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_19"> 5000000 </us-gaap:PreferredStockSharesAuthorized>

<us-gaap:PreferredStockSharesIssued contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_20"> 0 </us-gaap:PreferredStockSharesIssued>

<us-gaap:CommonStockSharesIssued contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_25"> 100047331 </us-gaap:CommonStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_21"> 0 </us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_18"> 0.0001 </us-gaap:PreferredStockParOrStatedValuePerShare>

<us-gaap:LiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_12"> 15834000 </us-gaap:LiabilitiesCurrent>

<us-gaap:AdditionalPaidInCapital contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_27"> 807631000 </us-gaap:AdditionalPaidInCapital>

<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_2_1"> 4167000 </us-gaap:EmployeeRelatedLiabilitiesCurrent>

<us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_11"> 13818000 </us-gaap:AccruedLiabilitiesCurrent>

<us-gaap:Liabilities contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_14"> 15969000 </us-gaap:Liabilities>

<us-gaap:LiabilitiesNoncurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_13"> 135000 </us-gaap:LiabilitiesNoncurrent>

<us-gaap:CommonStockValue contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_22"> 10000 </us-gaap:CommonStockValue>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_8_2"> 32000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_29"> -9000 </us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>

<us-gaap:CommitmentsAndContingencies contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_15"/>

<us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_2_2"> 1497000 </us-gaap:AccruedProfessionalFeesCurrent>

<us-gaap:PreferredStockValue contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_17"/>

<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_2_3"> 340000 </us-gaap:OtherAccruedLiabilitiesCurrent>

<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_28"> -498143000 </us-gaap:RetainedEarningsAccumulatedDeficit>

<us-gaap:StockholdersEquity contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_30"> 309489000 </us-gaap:StockholdersEquity>

<us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_31"> 325458000 </us-gaap:LiabilitiesAndStockholdersEquity>

<us-gaap:AccountsPayableCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_10"> 2016000 </us-gaap:AccountsPayableCurrent>

<us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_6"> 553000 </us-gaap:PropertyPlantAndEquipmentNet>

<us-gaap:AssetsCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_5"> 324618000 </us-gaap:AssetsCurrent>

<us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_1001_10"> 322055000 </us-gaap:InvestmentsFairValueDisclosure>

<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_3001_26"> 61854000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>

<us-gaap:Assets contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_8"> 325458000 </us-gaap:Assets>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_8_3"> 47000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>

<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_4"> 1168000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_8_1"> 260647000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:OtherAssetsNoncurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_7"> 287000 </us-gaap:OtherAssetsNoncurrent>

<us-gaap:InterestReceivableCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_3"> 964000 </us-gaap:InterestReceivableCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_2"> 260632000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<acad:AccruedClinicalDevelopmentServices contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_8866E476-EB20-46E3-9D91-E94DE27CEBD2_2_0"> 7814000 </acad:AccruedClinicalDevelopmentServices>

<us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1105250" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_1002_10"> 51173000 </us-gaap:InvestmentsFairValueDisclosure>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1105250_1113760x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_4002_6"> 2750000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1105250_1113971x1108237" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_6002_5"> 48423000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>

<us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1110677" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_1003_10"> 270882000 </us-gaap:InvestmentsFairValueDisclosure>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1110677_1113760x1108496" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_2003_9"> 22999000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1110677_1113760x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_3003_7"> 110235000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1109902x1110677_1113760x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_5003_8"> 137648000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1113760x1108496" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_2001_9"> 22999000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1113760x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_3001_7"> 110235000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1113760x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_4001_6"> 2750000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1113760x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_5001_8"> 137648000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1113971x1108237" unitRef="iso4217_USD" decimals="-3" id="id_5138751_6993E5DA-4B75-4D24-8656-5EBD99522F26_6001_5"> 48423000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1108496" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_7_2"> 19000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1108496" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_7_1"> 22980000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1108496" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_7_4"> 22999000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_5_2"> 8000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_5_3"> 10000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_5_1"> 97237000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1111781" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_5_4"> 97235000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_4_2"> 2000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_4_1"> 2748000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114216" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_4_4"> 2750000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_6_2"> 3000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>

<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_6_3"> 37000 </us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>

<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_6_1"> 137682000 </us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>

<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="eol_PE81806---1510-Q0007_STD_0_20141231_0_1116388x1114726" unitRef="iso4217_USD" decimals="-3" id="id_5138751_7713B4DB-BF92-4063-95F5-E76AAFDFDF33_6_4"> 137648000 </us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_4_2"> 9595000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_14"> -31149000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

<us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_11"> -0.41 </us-gaap:EarningsPerShareBasicAndDiluted>

<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_12"> 96042000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_9"> -68000 </us-gaap:IncreaseDecreaseInOtherOperatingAssets>

<us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_4_4"> -39277000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_18"> 6000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_4"> 11000 </us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>

<us-gaap:OperatingIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_8"> -39681000 </us-gaap:OperatingIncomeLoss>

<us-gaap:Revenues contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_1"> 58000 </us-gaap:Revenues>

<us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_7"> 570000 </us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>

<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_8"> 1261000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_9"> 358000 </us-gaap:InterestIncomeExpenseNonoperatingNet>

<us-gaap:NetIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_10"> -39323000 </us-gaap:NetIncomeLoss>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_4_2"> 46000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_16"> 288639000 </us-gaap:PaymentsToAcquireAvailableForSaleSecurities>

<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_21"> 199762000 </us-gaap:ProceedsFromIssuanceOfCommonStock>

<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_17"> 122023000 </us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>

<us-gaap:OperatingExpenses contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_7"> 39739000 </us-gaap:OperatingExpenses>

<us-gaap:Depreciation contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_5"> 85000 </us-gaap:Depreciation>

<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_22"> 199762000 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

<us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_5"> 14272000 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_12"> -26000 </us-gaap:IncreaseDecreaseInDeferredRevenue>

<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_24"> 1991000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_3"> 7493000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_13"> 10000 </us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>

<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_10"> 732000 </us-gaap:IncreaseDecreaseInAccountsPayable>

<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_11"> 1654000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>

<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_2_19"> -166622000 </us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

<us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_4_3"> 25467000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0_1112578x1104556" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_1004_0"> 7629000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0_1112578x1108838" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_2004_1"> 1966000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0_1113993x1105782" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1004_6"> 5398000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20140630_0_1113993x1109593" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2004_4"> 2095000 </us-gaap:AllocatedShareBasedCompensationExpense>

<dei:DocumentType contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_F64FDB99-1E7F-4C06-BB41-89C350E8E50C_1_0"> 10-Q </dei:DocumentType>

<dei:TradingSymbol contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_88887BCF-A46D-4262-A6B7-B8A6F17F0ADF_1_0"> ACAD </dei:TradingSymbol>

<us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_27168669-D99F-4ADD-AB64-07746008C301_1_0">

<div> Investment securities, all classified as available-for-sale, consisted of the following (in thousands): <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" nowrap="nowrap" align="center">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Estimated Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">164,891</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">164,894</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,672</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,671</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177,563</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(11</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177,565</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasury notes </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,748</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,750</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97,237</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97,235</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,682</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,648</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Commercial paper </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,980</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,999</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">260,647</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(47</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">260,632</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>

<dei:EntityCentralIndexKey contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_88887BCF-A46D-4262-A6B7-B8A6F17F0ADF_1_2"> 0001070494 </dei:EntityCentralIndexKey>

<dei:DocumentPeriodEndDate contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_F64FDB99-1E7F-4C06-BB41-89C350E8E50C_1_2"> 2015-06-30 </dei:DocumentPeriodEndDate>

<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_CFF1D641-17EA-4ACD-A5C3-79D31F85BDAE_1_0">

<div> 5. Investment Securities Investment securities, all classified as available-for-sale, consisted of the following (in thousands): <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" nowrap="nowrap" align="center">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Estimated Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">164,891</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">164,894</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,672</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,671</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177,563</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(11</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177,565</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="63%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized Cost</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized Gains</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unrealized Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> U.S. Treasury notes </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,748</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,750</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97,237</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97,235</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,682</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,648</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Commercial paper </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,980</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,999</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">260,647</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(47</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">260,632</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> At each reporting date, the Company performs an evaluation of impairment to determine if the unrealized losses are other-than-temporary. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition of the issuer, and the Company’s intent and ability to hold the investment until recovery of its amortized cost basis. The Company intends, and has the ability, to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. Based on its evaluation, the Company determined that its unrealized losses were not other-than-temporary at June 30, 2015 and December 31, 2014. As of June 30, 2015 and December 31, 2014, all of the Company’s available-for-sale investment securities had contractual maturity dates of less than one year. </div>

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>

<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_D4FCAC4F-C086-459A-B907-D646114528F8_1_0">

<div> 4. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued research and development services </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,585</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,814</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued compensation and benefits </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,528</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued consulting and professional fees </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,666</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,497</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,683</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,462</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,818</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

<dei:EntityFilerCategory contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_88887BCF-A46D-4262-A6B7-B8A6F17F0ADF_1_4"> Large Accelerated Filer </dei:EntityFilerCategory>

<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_8450A9D6-F863-4916-A225-4A9BFD8C21AB_1_0">

<div> The fair value of each employee stock option and each employee stock purchase right granted is estimated on the grant date under the fair value method using the Black-Scholes valuation model. The estimated fair value of each stock option and purchase right, including the effect of estimated forfeitures, is then expensed over the requisite service period, which is generally the vesting period. </div>

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_00D1D7DA-F217-4887-9275-B0EB44393737_1_0">

<div> 3. Stock-Based Compensation The fair value of each employee stock option and each employee stock purchase right granted is estimated on the grant date under the fair value method using the Black-Scholes valuation model. The estimated fair value of each stock option and purchase right, including the effect of estimated forfeitures, is then expensed over the requisite service period, which is generally the vesting period. The Company recognized stock-based compensation expense of $7.5 million and $22.0 million during the three and six months ended June 30, 2015, respectively, and $4.3 million and $7.5 million during the three and six months ended June 30, 2014, respectively. During the first quarter of 2015, the Company entered into a transition agreement with Uli Hacksell, Ph.D., the Company’s former Chief Executive Officer, in connection with his retirement from the Company in March 2015. Stock-based compensation expense for the first quarter of 2015 included a one-time $9.0 million charge representing the fair value of the outstanding options expected to vest over the term of the transition agreement as valued on the retirement date. As of June 30, 2015, total unrecognized compensation cost related to stock options and purchase plan rights was approximately $86.2 million, which is expected to be recognized over a weighted-average period of 3.1 years. </div>

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_3_2"> 11294000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_B21480FE-B082-4677-943B-09746073BD61_1_0">

<div> Accrued liabilities consisted of the following (in thousands): <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued research and development services </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,585</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,814</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued compensation and benefits </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,528</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,167</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued consulting and professional fees </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,666</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,497</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,683</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">340</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,462</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,818</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>

<dei:CurrentFiscalYearEndDate contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_88887BCF-A46D-4262-A6B7-B8A6F17F0ADF_1_3"> --12-31 </dei:CurrentFiscalYearEndDate>

<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_05632B07-EA3F-463E-9603-6F3DB4CB35B4_1_2"> P3Y1M6D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

<dei:DocumentFiscalPeriodFocus contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_F64FDB99-1E7F-4C06-BB41-89C350E8E50C_1_4"> Q2 </dei:DocumentFiscalPeriodFocus>

<us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_3FB4FDD9-452C-4052-A38C-69C87E1507D6_1_0">

<div> 6. Fair Value Measurements As of June 30, 2015, the Company held $270.5 million of cash equivalents and available-for-sale investment securities consisting of a money market fund and high quality, marketable debt instruments of corporations, financial institutions and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least A3/A- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard & Poor’s. The Company’s cash equivalents and available-for-sale investment securities are classified within the fair value hierarchy as defined by authoritative guidance. The Company’s investment securities classified as Level 1 are valued using quoted market prices. The Company obtains the fair value of its Level 2 financial instruments from third party pricing services. The pricing services utilize industry standard valuation models whereby all significant inputs, including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, bids, offers, or other market-related data, are observable. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and matrices, and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of June 30, 2015 and December 31, 2014, respectively. The Company does not hold any securities classified as Level 3, which are securities valued using unobservable inputs. The Company has not transferred any investment securities between the classifications. The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center">Fair Value Measurements at Reporting Date Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Money market fund </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">92,977</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">92,977</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">164,894</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">164,894</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,671</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,671</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">270,542</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">92,977</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177,565</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center">Fair Value Measurements at Reporting Date Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> December 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Money market fund </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,423</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,423</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> U.S. Treasury notes </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,750</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,750</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,235</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,235</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Commercial paper </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,999</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,999</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322,055</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,173</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">270,882</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:FairValueDisclosuresTextBlock>

<us-gaap:EarningsPerShareTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_A9D43004-AEB7-4C1E-9157-46FF59D07337_1_0">

<div> 2. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options and warrants are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive. Shares used in calculating basic and diluted net loss per common share exclude the following potential common shares as their effect is antidilutive (in thousands): <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Antidilutive options to purchase common stock </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,024</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,772</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,328</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,629</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Antidilutive warrants to purchase common stock </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,990</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,738</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,294</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,595</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:EarningsPerShareTextBlock>

<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_14"> -55220000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

<us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_6DEC3007-54B7-46EA-8457-CC1A16CDAD70_1_0">

<div> 9. Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance related to accounting for fees paid in a cloud computing arrangement. This accounting update provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual reporting periods beginning after December 15, 2015 and early adoption is permitted. The Company adopted this guidance in the first quarter of fiscal 2015 with no significant impact to its consolidated financial statements. In May 2014, the FASB issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The original guidance was effective for annual reporting periods beginning after December 15, 2016. However, in July 2015, the FASB agreed to delay the effective date by one year, with early adoption permitted, but not before the original effective date of the standard. In accordance with the agreed upon delay, the Company will adopt this guidance on January 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements. </div>

</us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted>

<dei:AmendmentFlag contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_F64FDB99-1E7F-4C06-BB41-89C350E8E50C_1_1"> false </dei:AmendmentFlag>

<us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_11"> -0.80 </us-gaap:EarningsPerShareBasicAndDiluted>

<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_985987AE-911D-435A-9FDC-9C9BD0CEAFD5_1_0">

<div> 1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of ACADIA Pharmaceuticals Inc. should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission (“SEC”). The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates. The Company has incurred substantial operating losses since its inception due in large part to expenditures for its research and development activities. As of June 30, 2015, the Company had an accumulated deficit of $577.9 million. The Company expects to continue to incur operating losses for at least the next several years as it pursues the development and commercialization of its product candidates. The Company may require significant additional financing in the future to fund its operations. Future capital requirements will depend on many factors, including the progress in, the outcome of and the costs of the Company’s development and regulatory activities, including the ability of the Company to obtain regulatory approval for its products, costs associated with establishing necessary sales and marketing capabilities, the amount of product sales, if any, the scope, prioritization and number of its research and development programs, the ability of its collaborators and the Company to reach milestones and other events or developments under its collaboration and license agreements, and the ability of the Company to enter into new, and to maintain existing, collaboration and license agreements. Unless and until the Company can generate significant cash from operations, it expects to fund its operations through its existing cash, cash equivalents and investment securities, payments from existing and potential future collaborations, proceeds from public or private sales of its equity securities, debt financing, grant funding, or by licensing all or a portion of its product candidates or technology. The Company cannot be certain that adequate additional funding will be available on acceptable terms, or at all. Conditions in the financial markets and other factors could have a material adverse effect on the Company’s ability to access sufficient funding on acceptable terms, or at all. If the Company needs but cannot raise adequate additional capital, it will be required to delay, reduce the scope of, or eliminate one or more of its research or development programs or its commercialization efforts. In such circumstances, the Company may also be required to relinquish greater, or even all, rights to product candidates at earlier stages of development or commercialization or on less favorable terms than it would otherwise choose. </div>

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

<dei:EntityRegistrantName contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_88887BCF-A46D-4262-A6B7-B8A6F17F0ADF_1_1"> ACADIA PHARMACEUTICALS INC </dei:EntityRegistrantName>

<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_49F8380B-4FB3-4C43-9DD3-FD1AC16D8DB3_1_0">

<div> The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center">Fair Value Measurements at Reporting Date Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Money market fund </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">92,977</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">92,977</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">164,894</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">164,894</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,671</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,671</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">270,542</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">92,977</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177,565</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center">Fair Value Measurements at Reporting Date Using</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> December 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"> Quoted Prices in Active Markets for Identical Assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Other Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Money market fund </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,423</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">48,423</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> U.S. Treasury notes </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,750</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,750</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Government sponsored enterprise securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,235</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,235</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Corporate debt securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">137,648</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Commercial paper </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,999</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,999</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">322,055</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">51,173</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">270,882</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> — </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>

<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="shares" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_12"> 100273000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_03FA08D5-3DE6-4911-A69F-1128F2C4EEB1_1_0">

<div> 7. Stockholders’ Equity Authorized Shares In June 2015, following approval by the Company’s stockholders, the Company filed a Certificate of Amendment of its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the number of authorized shares of common stock of the Company from 150,000,000 to 225,000,000. Equity Incentive Plan In June 2015, the Company’s stockholders approved an amendment to its 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,000,000 shares. Public Offering In March 2014, the Company raised net proceeds of $196.8 million from the sale of 7,360,000 shares of its common stock in a public offering, including 960,000 shares sold pursuant to the exercise in full of the underwriters’ over-allotment option. </div>

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

<dei:DocumentFiscalYearFocus contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_F64FDB99-1E7F-4C06-BB41-89C350E8E50C_1_3"> 2015 </dei:DocumentFiscalYearFocus>

<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_73799907-A721-4D37-889B-587208EB00A1_1_0">

<div> 8. Commitments and Contingencies External Services The Company has entered into agreements with contract research organizations and other external service providers primarily for services in connection with the development and planned commercialization of its product candidates. The Company was contractually obligated for up to approximately $29.7 million of future services under these agreements as of June 30, 2015. The nature of the work being conducted under the Company’s agreements with external service providers is such that, in most cases, the services may be stopped with short notice. In such event, the Company would not be liable for the full amount of the contract. The Company’s actual contractual obligations may vary depending upon several factors, including the progress and results of the underlying studies. Contingent Regulatory Milestone Payments In connection with the Company’s 2006 license agreement with the Ipsen Group, pursuant to which the Company licensed certain intellectual property rights that complement its patent portfolio for its serotonin platform, including NUPLAZID™ (pimavanserin), the Company may be obligated in future periods to make certain regulatory milestone payments. These milestone payments may never occur as they are contingent on the achievement of future regulatory events which may never be attained. These one-time payments include $2.5 million payable upon the successful filing of the first regulatory application with the U.S. Food and Drug Administration (“FDA”) and $8.0 million payable upon obtaining the first regulatory approval from the FDA. If NUPLAZID is approved, then the Company would make royalty payments to Ipsen of up to two percent on net product sales, if any. Legal Proceedings In March 2015, following the Company’s announcement of the update to the timing of its planned New Drug Application (“NDA”) submission to the FDA for NUPLAZID for the treatment of Parkinson’s disease psychosis and the subsequent decline of the price of its common stock, two putative securities class action complaints (captioned Rihn v. ACADIA Pharmaceuticals Inc., Case No. 15-cv-0575-BTM-DHB and Wright v. ACADIA Pharmaceuticals Inc., Case No. 15-cv-0593- BTM-DHB) were filed in the U.S. District Court for the Southern District of California, or the Court, against the Company and certain of its current and former officers. The complaints generally allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making materially false and misleading statements regarding the timing of the Company’s planned NDA submission to the FDA for NUPLAZID, thereby artificially inflating the price of its common stock. The complaints seek unspecified monetary damages and other relief. On April 10 and June 1, 2015, the Court entered orders deferring the defendants’ response to the Rihn and Wright complaints until after the Court appoints a lead plaintiff and assigns lead counsel. On May 12, 2015, several putative stockholders filed separate motions to consolidate the two actions and be appointed lead plaintiff. The Court has not yet issued an order on consolidation and lead plaintiff. The Company has assessed such legal proceedings, and given the unpredictability inherent in litigation, the Company cannot predict the outcome of these matters. At this time, the Company is unable to estimate possible losses or ranges of losses that may result from such legal proceedings, and it has not accrued any amounts in connection with such legal proceedings other than ongoing attorneys’ fees. </div>

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" id="id_5138751_95A5561C-2977-48CD-8B72-FEA49B85868B_1_0">

<div> Shares used in calculating basic and diluted net loss per common share exclude the following potential common shares as their effect is antidilutive (in thousands): <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"> Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Antidilutive options to purchase common stock </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,024</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,772</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,328</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,629</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Antidilutive warrants to purchase common stock </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,966</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,990</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,738</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,294</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,595</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px; font-size:4pt"> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td> </td> </tr> </table> </div>

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>

<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_9"> 46000 </us-gaap:IncreaseDecreaseInOtherOperatingAssets>

<us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_3_4"> -79733000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_18"> 1662000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_4"> 1115000 </us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>

<us-gaap:OperatingIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_8"> -80049000 </us-gaap:OperatingIncomeLoss>

<us-gaap:Revenues contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_1"> 5000 </us-gaap:Revenues>

<us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_7"> 544000 </us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>

<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_8"> -60000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_9"> 296000 </us-gaap:InterestIncomeExpenseNonoperatingNet>

<us-gaap:NetIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_10"> -79753000 </us-gaap:NetIncomeLoss>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_3_2"> 17000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_16"> 125255000 </us-gaap:PaymentsToAcquireAvailableForSaleSecurities>

<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_3_3"> 3000 </us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>

<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_21"> 4038000 </us-gaap:ProceedsFromIssuanceOfCommonStock>

<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_17"> 209454000 </us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>

<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_23"> 3000 </us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>

<us-gaap:OperatingExpenses contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_7"> 80054000 </us-gaap:OperatingExpenses>

<us-gaap:Depreciation contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_5"> 402000 </us-gaap:Depreciation>

<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_22"> 4038000 </us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

<us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_5"> 45380000 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_24"> 31358000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_3"> 22027000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_13"> 205000 </us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>

<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_10"> 900000 </us-gaap:IncreaseDecreaseInAccountsPayable>

<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_11"> 2644000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>

<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_1_19"> 82537000 </us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

<us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_3_3"> 34674000 </us-gaap:ResearchAndDevelopmentExpense>

<acad:RetirementDate contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0_1106131x1217177" id="id_5138751_045DE60A-9925-4B68-901C-B0D79F57029F_1001_0"> 2015-03-31 </acad:RetirementDate>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0_1112578x1104556" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_1003_0"> 9328000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0_1112578x1108838" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_2003_1"> 1966000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0_1113993x1105782" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1003_6"> 16826000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0_1113993x1109593" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2003_4"> 5201000 </us-gaap:AllocatedShareBasedCompensationExpense>

<acad:PaymentOfRoyaltyPercentageOnNetProductSales contextRef="eol_PE81806---1510-Q0007_STD_181_20150630_0_1115253x1116460" unitRef="pure" decimals="INF" id="id_5138751_56FF22F2-3752-4220-B192-1701C2CCDB39_2_2"> 0.02 </acad:PaymentOfRoyaltyPercentageOnNetProductSales>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE81806---1510-Q0007_STD_30_20150630_0_1105927x1260089" unitRef="shares" decimals="INF" id="id_5138751_BF1174BC-6738-4162-AB5A-CB54CFA062A8_1001_0"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>

<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE81806---1510-Q0007_STD_31_20140331_0" unitRef="shares" decimals="INF" id="id_5138751_C186F6AA-B370-4E39-81CD-6306A7D6A79F_1_1"> 7360000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>

<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE81806---1510-Q0007_STD_31_20140331_0" unitRef="iso4217_USD" decimals="-5" id="id_5138751_C186F6AA-B370-4E39-81CD-6306A7D6A79F_1_0"> 196800000 </us-gaap:ProceedsFromIssuanceOfCommonStock>

<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE81806---1510-Q0007_STD_31_20140331_0_1104490x1163248" unitRef="shares" decimals="INF" id="id_5138751_C186F6AA-B370-4E39-81CD-6306A7D6A79F_1001_2"> 960000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_90_20150331_0_1106131x1217177" unitRef="iso4217_USD" decimals="-5" id="id_5138751_05632B07-EA3F-463E-9603-6F3DB4CB35B4_1002_0"> 9000000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_2_2"> 9738000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_11"> -0.22 </us-gaap:EarningsPerShareBasicAndDiluted>

<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_12"> 99048000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

<us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_2_4"> -21401000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:OperatingIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_8"> -21723000 </us-gaap:OperatingIncomeLoss>

<us-gaap:Revenues contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_1"> 28000 </us-gaap:Revenues>

<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_9"> 228000 </us-gaap:InterestIncomeExpenseNonoperatingNet>

<us-gaap:NetIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_10"> -21495000 </us-gaap:NetIncomeLoss>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_2_2"> 94000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:OperatingExpenses contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_7"> 21751000 </us-gaap:OperatingExpenses>

<us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_5"> 7952000 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_5138751_4123FB4C-1ECE-459D-ADB2-BF64B67AB5B6_3_0"> 4300000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2_3"> 13799000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0_1112578x1104556" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_1002_0"> 7772000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0_1112578x1108838" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_2002_1"> 1966000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0_1113993x1105782" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1002_6"> 3242000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20140630_0_1113993x1109593" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2002_4"> 1089000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_1_2"> 11990000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_11"> -0.39 </us-gaap:EarningsPerShareBasicAndDiluted>

<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="shares" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_12"> 100349000 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

<us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_1_4"> -39371000 </us-gaap:ComprehensiveIncomeNetOfTax>

<us-gaap:OperatingIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_8"> -39497000 </us-gaap:OperatingIncomeLoss>

<us-gaap:Revenues contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_1"> 1000 </us-gaap:Revenues>

<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_9"> 119000 </us-gaap:InterestIncomeExpenseNonoperatingNet>

<us-gaap:NetIncomeLoss contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_10"> -39378000 </us-gaap:NetIncomeLoss>

<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_1_2"> 8000 </us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>

<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_DB9A0FAC-25D3-4616-BD38-5A3288A0D8BB_1_3"> -1000 </us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>

<us-gaap:OperatingExpenses contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_7"> 39498000 </us-gaap:OperatingExpenses>

<us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_5"> 21119000 </us-gaap:GeneralAndAdministrativeExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-5" id="id_5138751_4123FB4C-1ECE-459D-ADB2-BF64B67AB5B6_1_0"> 7500000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1_3"> 18379000 </us-gaap:ResearchAndDevelopmentExpense>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0_1112578x1104556" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_1001_0"> 10024000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0_1112578x1108838" unitRef="shares" decimals="-3" id="id_5138751_B271B72D-6DC3-493D-B60D-B1EF2F56D02C_2001_1"> 1966000 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0_1113993x1105782" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_1001_6"> 4660000 </us-gaap:AllocatedShareBasedCompensationExpense>

<us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE81806---1510-Q0007_STD_91_20150630_0_1113993x1109593" unitRef="iso4217_USD" decimals="-3" id="id_5138751_968D8FA5-8864-4A7A-9634-8AFFECAF0A7E_2001_4"> 2839000 </us-gaap:AllocatedShareBasedCompensationExpense>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis"> acad:FormerChiefExecutiveOfficerMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> acad:UnderwriterMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> acad:EquityIncentivePlanTwentyTenMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis"> acad:FormerChiefExecutiveOfficerMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis"> us-gaap:DomesticCorporateDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis"> us-gaap:USTreasurySecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis"> us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis"> us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis"> us-gaap:MoneyMarketFundsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:DomesticCorporateDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:USTreasurySecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:DomesticCorporateDebtSecuritiesMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis"> us-gaap:MoneyMarketFundsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:USTreasurySecuritiesMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis"> us-gaap:DomesticCorporateDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis"> us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis"> us-gaap:MoneyMarketFundsMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:DomesticCorporateDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis"> acad:MilestoneTwoMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis"> acad:MilestoneOneMember </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:DomesticCorporateDebtSecuritiesMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis"> us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis"> us-gaap:MoneyMarketFundsMember </xbrldi:explicitMember>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>

</segment>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

</entity>

</period>

</context>

<measure> shares </measure>

</unit>

</unit>

</unitNumerator>

<measure> shares </measure>

</unitDenominator>

</divide>

</unit>

</unit>

<xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">

<xbrll:loc xlink:href="#id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_3001_26" xlink:label="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_3001_26" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_10" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_10" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_11" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_11" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_12" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_12" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_13" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_13" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_14" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_14" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_15" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_15" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_17" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_17" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_18" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_18" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_19" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_19" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_2" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_2" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_20" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_20" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_21" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_21" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_22" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_22" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_23" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_23" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_24" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_24" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_25" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_25" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_26" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_26" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_27" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_27" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_28" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_28" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_29" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_29" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_3" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_3" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_30" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_30" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_31" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_31" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_4" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_4" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_5" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_5" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_6" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_6" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_7" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_7" xlink:type="locator"/>

<xbrll:loc xlink:href="#id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_8" xlink:label="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_8" xlink:type="locator"/>

<xbrll:footnote xlink:label="footnote_379464441" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> The condensed consolidated balance sheet at December 31, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. </xbrll:footnote>

<xbrll:footnoteArc xlink:from="id_5138751_1920B3B7-6F2F-4A3A-80C9-EAE30367095D_3001_26" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_10" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_11" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_12" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_13" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_14" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_15" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_17" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_18" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_19" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_2" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_20" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_21" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_22" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_23" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_24" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_25" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_26" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_27" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_28" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_29" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_3" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_30" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_31" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_4" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_5" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_6" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_7" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

<xbrll:footnoteArc xlink:from="id_5138751_630F7491-FCAB-4820-8569-A10CEE7AFB44_2_8" xlink:to="footnote_379464441" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>

</xbrll:footnoteLink>

</xbrl>

21 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/09/24  Acadia Pharmaceuticals Inc.       10-Q        3/31/24   62:7.2M                                   Donnelley … Solutions/FA
 2/28/24  Acadia Pharmaceuticals Inc.       10-K       12/31/23   88:14M                                    Donnelley … Solutions/FA
11/03/23  Acadia Pharmaceuticals Inc.       10-Q        9/30/23   63:8.1M                                   Donnelley … Solutions/FA
 8/03/23  Acadia Pharmaceuticals Inc.       10-Q        6/30/23   66:10M                                    Donnelley … Solutions/FA
 5/08/23  Acadia Pharmaceuticals Inc.       10-Q        3/31/23   59:7.7M                                   Donnelley … Solutions/FA
 2/28/23  Acadia Pharmaceuticals Inc.       10-K       12/31/22   79:15M                                    Donnelley … Solutions/FA
 2/07/23  Acadia Pharmaceuticals Inc.       S-8         2/07/23    7:268K                                   Donnelley … Solutions/FA
11/03/22  Acadia Pharmaceuticals Inc.       10-Q        9/30/22   60:9M                                     Donnelley … Solutions/FA
 8/09/22  Acadia Pharmaceuticals Inc.       S-8         8/09/22    5:190K                                   Donnelley … Solutions/FA
 8/09/22  Acadia Pharmaceuticals Inc.       10-Q        6/30/22   58:8.3M                                   Donnelley … Solutions/FA
 5/25/22  Acadia Pharmaceuticals Inc.       S-3ASR      5/25/22    4:265K                                   Donnelley … Solutions/FA
 5/05/22  Acadia Pharmaceuticals Inc.       10-Q        3/31/22   57:7.5M                                   Donnelley … Solutions/FA
 3/01/22  Acadia Pharmaceuticals Inc.       10-K       12/31/21   82:13M                                    Donnelley … Solutions/FA
11/09/21  Acadia Pharmaceuticals Inc.       10-Q        9/30/21   57:7.2M                                   ActiveDisclosure/FA
 8/05/21  Acadia Pharmaceuticals Inc.       10-Q        6/30/21   59:7.2M                                   ActiveDisclosure/FA
 5/06/21  Acadia Pharmaceuticals Inc.       10-Q        3/31/21   63:7.5M                                   ActiveDisclosure/FA
 2/25/21  Acadia Pharmaceuticals Inc.       10-K       12/31/20   80:13M                                    ActiveDisclosure/FA
11/04/20  Acadia Pharmaceuticals Inc.       10-Q        9/30/20   60:7.1M                                   ActiveDisclosure/FA
 8/25/20  Acadia Pharmaceuticals Inc.       S-3ASR      8/25/20    3:196K                                   Donnelley … Solutions/FA
 8/06/20  Acadia Pharmaceuticals Inc.       10-Q        6/30/20   57:6.9M                                   ActiveDisclosure/FA
 8/06/20  Acadia Pharmaceuticals Inc.       S-8         8/06/20    3:53K                                    Donnelley … Solutions/FA

↑Top

Filing Submission 0001193125-15-281018 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Acadia Pharmaceuticals Inc – ‘10-Q’ for 6/30/15 – ‘EX-101.INS’

On: Thursday, 8/6/15, at 4:11pm ET · For: 6/30/15 · Accession #: 1193125-15-281018 · File #: 0-50768

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-101.INS’ — XBRL Instance — acad-20150630

This Exhibit is an XBRL XML File.

21 Subsequent Filings that Reference this Filing

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents